



Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 20, 2018

MENLO PARK, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adverum's management is scheduled to present on Thursday, January 10, 2019 at 8:00am Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: www.adverum.com. The webcast will be available on the company's website for at least two weeks following the event.

About Adverum Biotechnologies, Inc.

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum's core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information please visit www.adverum.com.

Investor and Media Inquiries:

Katherine Bock
Vice President Investor Relations & Corporate Communications
Adverum Biotechnologies, Inc.
650-656-9347
kbock@adverum.com

 [ADVERUM_ID_RGB
200x49.jpg](#)

Source: Adverum Biotechnologies, Inc.